Lonza signs agreement to manufacture AstraZeneca’s COVID-19 treatment
BASEL: Lonza has signed an agreement with AstraZeneca to manufacture AZD7442, a combination of two long-acting antibodies (LAABs) for the potential prevention and treatment of...
Lonza appoints Pierre-Alain Ruffieux as new Chief Executive Officer
BASEL, SWITZERLAND: The Board of Lonza announced today that Pierre-Alain Ruffieux has been appointed Chief Executive Officer effective 1 November 2020. Prior to that he...
Moderna and Lonza announce strategic collaboration to manufacture vaccine against Novel Coronavirus
BASEL, SWITZERLAND: Moderna Inc., a clinical stage biotechnology company, and Lonza Ltd. have announced a 10-year strategic collaboration agreement to enable larger scale manufacture of...
Lonza expands Bioconjugation facility and announces approval of third commercial ADC
BASEL, SWITZERLAND: Lonza has announced the start of expansion to its bioconjugation facility in Visp, Switzerland together with the successful commercial approval of a third...